Where does MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER ranks #13,044 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER hold?

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER holds 23 US utility patents granted between 2015 and 2025, spanning 13 technology areas.

What is MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's Innovation Score?

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER has an Innovation Score of 32.5 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's patent grant rate increasing or decreasing?

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's recent grant velocity is -76% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's patents?

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's patents average 12.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER

Q: What technology areas does MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER focus on?

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 17 patents, ranking #1,155 of 6,058 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Q: How is the MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 23 granted patents across 13 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Max-delbrück-centrum ranks #13,044 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 13 technology areas.

#13,044
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.5/100): 12.8
avg claims per patent: -76%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13044 · Foreign Corporation #13,044 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 23 grants
MID-PACK #13,044/49,997
PHOTO-FINISH MAC Valves
CPC-FOCUS A61P · 13 areas
INNOV-THIN 32.5/100
CLAIMS-RICH 12.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -76% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: MAC Valves, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Max-delbrück-centrum’s 32.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.0 pts (34%) Velocity 1.1 pts (3%) Breadth 12.7 pts (39%) Claim depth 7.7 pts (24%)

Qualcomm Incorporated · highest

85
MAX-DELBRÜCK-CENTRUM… · this assignee

33
3D Lighting… · lowest

7

What this shows Max-delbrück-centrum's Innovation Score is 32.5/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Max-delbrück-centrum?

Each dot is one of Max-delbrück-centrum’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Max-delbrück-centrum’s own 12.8 claims/patent is ABOVE the 9.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Max-delbrück-centrum vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Max-delbrück-centrum's grants concentrate

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER is a focused PatentsView assignee: 13 CPC subclasses with 73.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (5 grants) versus a trough of 1 in 2017. By volume, Max-delbrück-centrum sits between MAC Valves, Inc. and Morimura Sofc Technology Co., Ltd..

Max-delbrück-centrum's three-year grant acceleration

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER shows 1 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

MAC Valves

23
Mack Rides & KG

23
Marco VAN Noort B…

23
Matsutani Chemica…

23
Medtrade Products

23
Micro-tech (Nanji…

23
Ming CHI Universi…

23
Morimura Sofc Tec…

23
Max-delbrÜCk-cent… ◀

23

What this shows MAX-DELBRÜCK-CENTRUM holds 23 patents at rank #13,035, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near MAX-DELBRÜCK-CENTRUM

By rank, the assignees closest to #13,035 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in MAX-DELBRÜCK-CENTRUM's primary technology class.

Max-delbrück-centrum's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	17.4%
2016	5	21.7%
2017	1	4.3%
2018	4	17.4%
2019	3	13.0%
2020	2	8.7%
2021	1	4.3%
2022	1	4.3%
2025partial year	2	8.7%

Which technologies does MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C07K - Peptides 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

C07D - Heterocyclic Compounds 5

C07C - Acyclic OR Carbocyclic Compounds 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

Y02A - Technologies FOR Adaptation TO Climate Change 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

H01J - Electric Discharge Tubes OR Discharge Lamps 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's patent record in context - here's where to go next.

MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 73.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #13,044 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare MAX-DELBRÜCK-CENTRUM FÜR Molekulare Medizin IN DER against MAC Valves, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.